Concurrent allorecognition has a limited impact on posttransplant vaccination

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1361-1368

  Manzo, Teresa ^a,b   Michelini, Rodrigo Hess ^a   Basso, Veronica ^a   Ricupito, Alessia ^a,b   Chai, Jian Guo ^c   Simpson, Elizabeth ^c   Bellone, Matteo ^a   Mondino, Anna ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUMOR ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MODEL; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; BONE MARROW CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; FEMALE; H-Y ANTIGEN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION, HOMOLOGOUS;

EID: 79251581600     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002030     Document Type: Article

References (47)

1. Simpson, E., D. Roopenian, and E. Goulmy. 1998. Much ado about minor histocompatibility antigens. Immunol. Today 19: 108-112. (Pubitemid 28194655)
2. Hambach, L., and E. Goulmy. 2005. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr. Opin. Immunol. 17: 202-210.
3. Goulmy, E. 1996. Human minor histocompatibility antigens. Curr. Opin. Immunol. 8: 75-81.
4. Gordon, R. D., E. Simpson, and L. E. Samelson. 1975. In vitro cell-mediated immune responses to the male specific(H-Y) antigen in mice. J. Exp. Med. 142: 1108-1120.
5. Rötzschke, O., K. Falk, H. J. Wallny, S. Faath, and H. G. Rammensee. 1990. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249: 283-287.
6. Simpson, E., D. Scott, E. James, G. Lombardi, K. Cwynarski, F. Dazzi, M. Millrain, and P. J. Dyson. 2002. Minor H antigens: genes and peptides. Transpl. Immunol. 10: 115-123.
7. Candinas, D., B. K. Gunson, P. Nightingale, S. Hubscher, P. McMaster, and J. M. Neuberger. 1995. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 346: 1117-1121.
8. Randolph, S. S., T. A. Gooley, E. H.Warren, F. R. Appelbaum, and S. R. Riddell. 2004. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 103: 347-352.
9. Dazzi, F., R. M. Szydlo, N. C. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley, and J. M. Goldman. 2000. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96: 2712-2716.
10. Dickinson, A. M., X. N. Wang, L. Sviland, F. A. Vyth-Dreese, G. H. Jackson, T. N. Schumacher, J. B. Haanen, T. Mutis, and E. Goulmy. 2002. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8: 410-414.
11. Hambach, L., E. Spierings, and E. Goulmy. 2007. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract. Res. Clin. Haematol. 20: 171-187.
12. Seggewiss, R., and H. Einsele. 2010. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115: 3861-3868.
13. Razonable, R. R., and A. J. Eid. 2009. Viral infections in transplant recipients. Minerva Med. 100: 479-501.
14. Yi, Q. 2009. Novel immunotherapies. Cancer J. 15: 502-510.
15. Teshima, T., N.Mach, G. R. Hill, L. Pan, S. Gillessen, G.Dranoff, and J. L. Ferrara. 2001. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61: 162-171.
16. Melchionda, F., M. K. McKirdy, F. Medeiros, T. J. Fry, and C. L. Mackall. 2004. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J. Immunother. 27: 329-338.
17. Borrello, I., E. M. Sotomayor, F. M. Rattis, S. K. Cooke, L. Gu, and H. I. Levitsky. 2000. Sustaining the graft-versus-tumor effect through post-transplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95: 3011-3019.
18. Capitini, C. M., S. Herby, M. Milliron, M. R. Anver, C. L. Mackall, and T. J. Fry. 2009. Bone marrow deficient in IFN-g signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood 113: 5002-5009.
19. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
20. Choi, E. Y., Y. Yoshimura, G. J. Christianson, T. J. Sproule, S. Malarkannan, N. Shastri, S. Joyce, and D. C. Roopenian. 2001. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J. Immunol. 166: 4370-4379.
21. Millrain, M., P. Chandler, F. Dazzi, D. Scott, E. Simpson, and P. J. Dyson. 2001. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J. Immunol. 167: 3756-3764.
22. + T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
23. + T cell immunodominance. J. Immunol. 181: 2124-2133.
24. + T cells in response to infection is markedly efficient. Science 325: 1265-1269.
25. La Gruta, N. L., W. T. Rothwell, T. Cukalac, N. G. Swan, S. A. Valkenburg, K. Kedzierska, P. G. Thomas, P. C. Doherty, and S. J. Turner. 2010. Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J. Clin. Invest. 120: 1885-1894.
26. Hess Michelini, R., M. Freschi, T. Manzo, E. Jachetti, E. Degl'Innocenti, M. Grioni, V. Basso, C. Bonini, E. Simpson, A. Mondino, and M. Bellone. 2010. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res. 70: 3505-3514.
27. + T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3: 844-851.
28. Greenfield, A., D. Scott, D. Pennisi, I. Ehrmann, P. Ellis, L. Cooper, E. Simpson, and P. Koopman. 1996. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet. 14: 474-478.
29. + T cell survival but not for antigen proliferation. Nat. Immunol. 1: 54-58.
30. Scott, D., C. Addey, P. Ellis, E. James, M. J. Mitchell, N. Saut, S. Jurcevic, and E. Simpson. 2000. Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity 12: 711-720.
31. Camporeale, A., A. Boni, G. Iezzi, E. Degl'Innocenti, M. Grioni, A. Mondino, and M. Bellone. 2003. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res. 63: 3688-3694. (Pubitemid 36793053)
32. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
33. Degl'Innocenti, E., M. Grioni, A. Boni, A. Camporeale, M. T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N. M. Greenberg, and M. Bellone. 2005. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35: 66-75.
34. Simpson, E., D. Scott, and P. Chandler. 1997. The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning. Annu. Rev. Immunol. 15: 39-61.
35. Bourgeois, C., and B. Stockinger. 2006. T cell homeostasis in steady state and lymphopenic conditions. Immunol. Lett. 107: 89-92.
36. Laylor, R., H. Dewchand, E. Simpson, and F. Dazzi. 2005. Engraftment of allogeneic hematopoietic stem cells requires both inhibition of host-versus-graft responses and 'space' for homeostatic expansion. Transplantation 79: 1484-1491. (Pubitemid 40847578)
37. Hubert, R. S., I. Vivanco, E. Chen, S. Rastegar, K. Leong, S. C. Mitchell, R. Madraswala, Y. Zhou, J. Kuo, A. B. Raitano, et al. 1999. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA 96: 14523-14528.
38. Garcia-Hernandez, Mde. L., A. Gray, B. Hubby, and W. M. Kast. 2007. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 67: 1344-1351.
39. Roopenian, D., E. Y. Choi, and A. Brown. 2002. The immunogenomics of minor histocompatibility antigens. Immunol. Rev. 190: 86-94.
40. Choi, E. Y., G. J. Christianson, Y. Yoshimura, N. Jung, T. J. Sproule, S. Malarkannan, S. Joyce, and D. C. Roopenian. 2002. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graftversus-host disease. Blood 100: 4259-4265.
41. Ditschkowski, M., A. H. Elmaagacli, and D. W. Beelen. 2010. H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD). Ann. Hematol. DOI 10.1007/s00277-010-0971-8.
42. Tedeschi, S. K., B. N. Savani, M. Jagasia, B. Engelhardt, C. Anasetti, A. J. Barrett, and S. Lee. 2010. Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 16: 1033-1036.
43. Feuchtinger, T., K. Opherk, O. Bicanic, M. Schumm, G. U. Grigoleit, K. Hamprecht, G. Jahn, R. Handgretinger, and P. Lang. 2010. Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T(helper) cell response. Cytotherapy 12: 945-950.
44. Amigorena, S., and A. Savina. 2010. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 22: 109-117.
45. Yoshimura, Y., R. Yadav, G. J. Christianson, W. U. Ajayi, D. C. Roopenian, and S. Joyce. 2004. Duration of alloantigen presentation and avidity of T cell antigen recognition correlate with immunodominance of CTL response to minor histocompatibility antigens. J. Immunol. 172: 6666-6674. (Pubitemid 38669102)
46. de Witte, M. A., M. Toebes, J. Y. Song, M. C. Wolkers, and T. N. Schumacher. 2007. Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood 109: 3830-3838.
47. Gratwohl, A., J. Hermans, J. Apperley, W. Arcese, A. Bacigalupo, G. Bandini, P. di Bartolomeo, M. Boogaerts, A. Bosi, E. Carreras, et al. 1995. Acute graftversus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 86: 813-818.